Top Markets
#1 OriginTrail OriginTrail +32.26%
#2 MarsCoin MarsCoin +16.10%
#3 Pons Pons +10.69%
#4 Waves Waves +10.39%
#5 Siren Siren +9.15%
#6 TROLL TROLL +8.50%
#7 Cysic Cysic +7.86%
#8 PulseChain PulseChain +5.89%
#9 Euler Euler +5.47%
#10 Falcon Finance Falcon Finance +4.92%
Coin of the day
OriginTrail OriginTrail
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Energenesis Biomedical CO.,LTD. Energenesis Biomedical CO.,LTD.

Energenesis Biomedical CO.,LTD.

6657
Rang in Aktien #22642
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered... Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.
Aktienkurs
$0.97305026
Zuletzt synchronisiert: 2026-08-21
Marktkapitalisierung
$85.54M
Veränderung (1 Tag)
1.16%
Veränderung (1 Jahr)
-50.40%
Land
TW
Handel Energenesis Biomedical CO.,LTD. (6657)

Kategorie

Healthcare
Gewinn für Energenesis Biomedical CO.,LTD. (6657)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Energenesis Biomedical CO.,LTD. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Energenesis Biomedical CO.,LTD. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH